Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
The renin-angiotensin system (RAS) is involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and represents a potential therapeutic target for NAFLD. Glucagon-like peptide-1 (GLP-1) signaling has been shown to regulate the RAS within various local tissues. In this study, we aimed...
Saved in:
Main Authors: | Mengying Yang (Author), Xiaoyi Ma (Author), Xiuping Xuan (Author), Hongjun Deng (Author), Qi Chen (Author), Li Yuan (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
by: Luo Y, et al.
Published: (2019) -
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
by: Tingli Guo, et al.
Published: (2023) -
Renin-Angiotensin Aldosterone System
Published: (2021) -
Renin-Angiotensin System Past, Present and Future
Published: (2017) -
New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Overview of Regulation of the Renin-Angiotensin-Aldosterone System
by: Akira Nishiyama, et al.
Published: (2010)